// App-Quantinova.ai

VP42.04 : The feasibility of implementation of pre-eclampsia screening and prevention

Researchers

Presenter

  • J.M. Johnson

Principal Investigators

  • J. Walsh

  • A. Wright

  • D. Wright

  • M. Pastuck

  • J. Loeffler

  • R. Chadha

  • S. Dwinnell

  • V. Kuret

  • H. Mahallati

  • C. O'Quinn

  • K. Paterson

  • J. Pollard

  • J. Schachar

  • N. Soliman

  • K. Nerenberg

  • D. McNeil

  • D.W. Johnson

Medical Centers

  • Diagnostic Imaging, University of Calgary, Calgary, AB, Canada

  • University of Calgary, Calgary, AB, Canada

  • Medicine and Oncology, University of Calgary, Calgary, AB, Canada

  • University of Exeter, Exeter, United Kingdom

  • University of Calgary, Calgary, AB, Canada

  • University of Plymouth, Devon, United Kingdom

Locations

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Obstetrics/Gynecology

Disease

  • Preeclampsia

Biomarkers

  • Placental growth factor

  • Pregnancy-associated plasma protein A

Drug/Treatment

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved